The inhibitors of this axis are extensively tested in both preclinical and clinical studies, including antibodies, small molecule inhibitors, and siRNAs, etc.[22, 36] CCL2 is also a potent attractant to recruit monocytes into primary and metastatic tumor sites. Here, CCL2 is linked to neoplasm.